News about Gilead Sciences
The economy and the stock market don’t always march in lockstep, and investors got a sharp reminder of that fact this fall. Parade-and-fireworks-worthy GDP growth and employment numbers shared the spotlight with an ugly market slide that took some previously beloved stocks into bear-market territory. Fears about inflation and trade tensions were among the culprits; […]
The blockbuster public offering pegs Allogene's market value at more than $2 billion.
Celgene and Novartis are among the companies accused of thwarting generic drugs.
On hot technologies like CRISPR and CAR-T, China has a leg up, Goldman says.